'Fast Facts: Follicular Lymphoma' provides an introduction to follicular lymphoma for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, classification, and risk assessment, together with existing approaches to treatment and monitoring. Looking into the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with FL.

Follicular lymphoma is a slow-growing type of blood cancer involving the lymph nodes. It is the most common type of slow-growing lymphoma, and is more commonly diagnosed in people older than 60, but adults of any age can be affected. Swollen lymph nodes are often the first sign. Follicular lymphoma cannot be completely cured but treatment is available that allows many people to have a normal lifespan and a good quality of life.

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.

This volume is the first of its kind to emphasize the visual approach in the diagnosis of cutaneous lymphoid infiltrates. Written and designed in an accessible yet highly detailed format by an expert in the field, this book bridges the knowledge gaps so often found when dealing with skin lymphomas. Complete with more than two hundred high quality images and illustrations, Diagnosis of Cutaneous Lymphoid Infiltrates offers pearls and pitfalls as well as differential diagnoses. Additionally, images are explained and decoded with the use of illustrations and analogies, proving to be an invaluable resource for pathologists, dermatologists, dermatopathologists, hematopathologists, and residents and fellows in these fields.

For nearly 25 years, Ferri's concise, pocket-sized resource has served as the go-to reference for practical, clinical information among students, residents, and other medical professionals. Formerly known as Practical Guide to the Care of the Medical Patient, this volume continues to provide a fast, effective, and efficient way to identify the important clinical, laboratory, and diagnostic imaging information you need to get through your internal medicine clerkship or residency. - Consult this title on your favorite device, conduct rapid searches, and adjust font sizes for optimal readability. - Benefit from the expert guidance of Dr. Fred Ferri, a leading teacher, clinician, and author. - Confidently manage patients with the latest clinical information, drug therapies, and lab tests. - Apply the latest knowledge and techniques with this updated and streamlined title, which still stays true to the Ferri name. - Quickly find important information with content organized into three major sections: Section I, titled "Surviving the Wards," contains information on charting, laboratory evaluation and formulary; Section II provides the differential diagnosis of common signs and symptoms likely to be encountered in the acute care setting; Section III has been completely revised and subdivided into 11 specialty specific diseases and disorders. - Carry just the sections you need, add personalized materials, and keep everything together and safe with an improved ring binder and design. - Access the full text and procedural videos online at Expert Consult.

Cutaneous T-cell lymphoma (CTCL) has been described as a 'great mimicker'. The correct diagnosis hinges on effective collaboration between clinicians and pathologists to correlate pathological and clinical findings. The patient's history, lesion description and diagnostic work-up will help the pathologist interpret the histopathology, whilst the clinician’s diagnosis is aided by a clear understanding the terminology used in the pathology report. The treatment of early and advanced mycosis fungoides and its variants is potentially lifelong, with patients typically cycling among treatments, interspersed with periods of expectant therapy providing palliation and symptomatic relief. Effective management requires knowledge of the wide range of options, how they are used, and their side-effect profile, in order to tailor treatment to the individual patient.